The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 2 study of vincristine and irinotecan in metastatic diffuse anaplastic Wilms tumor: Results from the Children’s Oncology Group AREN0321 study.
Najat C. Daw
No relevant relationships to disclose
James Robert Anderson
No relevant relationships to disclose
Fredric A. Hoffer
No relevant relationships to disclose
James I. Geller
No relevant relationships to disclose
John A. Kalapurakal
No relevant relationships to disclose
Elizabeth Jones Perlman
No relevant relationships to disclose
Peter F. Ehrlich
No relevant relationships to disclose
Elizabeth Anne Mullen
No relevant relationships to disclose
Eric J. Gratias
No relevant relationships to disclose
Paul Edward Grundy
No relevant relationships to disclose
Jeffrey S. Dome
No relevant relationships to disclose